AbbVie has reached an agreement to pay up to $2.54 billion to develop cancer treatments with Disco Pharmaceuticals, a private biotechnology company based in Germany. The announcement was made by Disco Pharmaceuticals on Thursday, November 19, 2026.
The American biopharmaceutical company, AbbVie, specializes in areas including oncology, immunology, and neuroscience. Disco Pharmaceuticals focuses on targeted cancer therapies. This agreement represents an early-stage move by the drug maker to pursue next-generation bispecific therapies, a class of medicines that can bind to two targets at once.
Under the terms of the deal, Disco will receive $40 million upfront and is eligible for up to $2.5 billion in milestone payments to develop AND-gated bispecific therapeutics for solid tumors. The company will also be eligible for tiered royalties on worldwide net sales. The AND-gated approach is designed to recognize cancer cells only when two target proteins are present simultaneously, which could potentially reduce damage to healthy tissue.
Disco CEO Mark Manfredi stated that his company will be responsible for the research and discovery. AbbVie will hold the right to exclusively license selected programs for further development, though this option only applies after Disco completes specified research. Manfredi said, "(AbbVie) brings a wealth of information, a wealth of experience in target biology, so we will learn from them and we will work with them on how to select targets," during the announcement.
The deal is currently at a very early stage. Disco Pharmaceuticals did not disclose the number of programs covered or the timeline for entering clinical development. However, Manfredi noted that Disco has been developing AND-gated therapies for colorectal cancer and small-cell lung cancer, and the company intends to select a development candidate in the second half of next year.






